Acrx stock forecast.

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Athersys Inc have a median target of 5.50, with a high estimate of 5.50 and a low estimate of 5.50. The median estimate ...Earnings announcement* for ACRX: May 15, 2023. AcelRx Pharmaceuticals, Inc. is estimated to report earnings on 05/15/2023. The upcoming earnings date is derived from an algorithm based on a ...AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at AcelRx Pharmaceuticals Inc’s stock grades for value, growth and quality.Nabriva Therapeutics plc (NASDAQ:NBRV) announced its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($13.25) EPS for the quarter, beating analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analysts' expectations of …Track Acelrx Pharmaceuticals Inc (ACRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Buy or Hold candidate since Nov 24, 2023 Loss -0.71% PDF. The AcelRx Pharmaceuticals stock price fell by -4.70% on the last day (Wednesday, 29th Nov …

2 Wall Street analysts have issued twelve-month price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price targets range from $4.25 to $5.00. On average, they expect the company's share price to reach $4.63 in the next twelve months. This suggests a possible upside of 670.8% from the stock's current price.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript November 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-1.58.May 9, 2023 · ACRX competes with other companies such as ATXI, PTIX, and PBLA. On May 9, 2023, ATXI stock remained unchanged, while PTIX stock increased by 2.06%. In contrast, PBLA stock decreased by 21.71%. ACRX is set to report its next earnings on May 11, 2023. ACRX operates in the health technology sector and is involved in the major pharmaceuticals ... Stock Price Forecast The 2 analysts offering 12-month price forecasts for Acurx Pharmaceuticals Inc have a median target of 11.50, with a high estimate of 13.00 and a low estimate of 10.00. Cash Ratio forecast for AcelRx Pharmaceuticals (ACRX) stock. Annual Cash Ratio forecast for AcelRx Pharmaceuticals stock for 2021 is 1.08299256789893. It is increase 0.39% from the last annual Cash Ratio report of 1.07883329659834. Annual Cash Ratio forecast for 2022 is 1.07667132533243, and 2023 is 1.07669258943835.

Jan 14, 2021 · What's ACRX's stock forecast? By Mohit Oberoi, CFA. Jan. 14 2021, Published 8:19 a.m. ET. Source: Unsplash. AcelRx (ACRX) stock made a new 52-week high of $2.12 on Jan. 12. However, the stock fell ...

ACRX stock forecast Our latest prediction for Acelrx Pharmaceuticals Inc's stock price was made on the Sept. 14, 2023 when the stock price was at 0.88$ . In the short term (2weeks), ACRX's stock price should underperform the market by -3.79% .

Find real-time NBY - NovaBay Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. 222.96%. Free cash flow. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -4.11M. 12.66%. Get the latest Achieve Life Sciences Inc ...Baudax Bio Stock Forecast and Price Target. ... ACRX Stock Forecast: AcelRx Pharmaceuticals Buy 6 $0.69 Buy/Sell: $4.25 571.01% Baudax Bio Revenue Forecast for 2023 - 2025 - 2030. In the last two years, Baudax Bio's Revenue has grown, increasing from $490.00k to $1.27M – a growth of 159.18%.Stock Price Forecast. The 2 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. The median estimate represents a +617.05% increase from the last price of 0.65. Stock Price Forecast. The 2 analysts offering 12-month price forecasts for NovaBay Pharmaceuticals Inc have a median target of 6.65, with a high estimate of 9.50 and a low estimate of 3.80. The ...

A stock with insider buying, one presenting data next year, and a total dog walk into a bar... I'll keep it short and sweet. New article on KPLT LPTX…Current. -$0.21. 1 Month Ago. -$0.48. 3 Months Ago. -$0.63. AcelRx Pharmaceuticals Inc. analyst estimates, including ACRX earnings per share estimates and analyst recommendations. Nov 3, 2023 · ACRX U.S.: Nasdaq AcelRx Pharmaceuticals Inc. Watch list Alert NEW Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Price Forecast. The 2 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. The ...

Forecast . Price target. 4.63 0.00 0.00%. The 2 analysts offering 1 year price forecasts for ACRX have a max estimate of — and a min estimate of —. Analyst rating. Based on 2 analysts giving stock ratings to ACRX in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreAcelRx Pharmaceuticals, Inc. 05 Apr, 2023, 08:30 ET. In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant. AcelRx announces full ...

ACRX is currently rated as a Sucker Stock | Stockopedia. Login Get Started. ... Is there a AcelRx Pharmaceuticals share price forecast for 2023? The analyst consensus target price for shares in AcelRx Pharmaceuticals is $4.12. That is …ACR's primary purpose was subsequently changed to that of an investment holding company with oil exploration as secondary purpose. On October 10, 1996, ACR completed its reorganization through a series of stock swaps, and as a result, some of the AG's established businesses became majority- or minority-owned subsidiaries of ACR.View the latest Ford Motor Co. (F) stock price, news, historical charts, analyst ratings and financial information from WSJ.Dec 1, 2023 · See the latest AcelRx Pharmaceuticals Inc stock price (ACRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. AcelRx Pharmaceuticals, Inc. 05 Apr, 2023, 08:30 ET. In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant. AcelRx announces full ...What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks) Aug-13-23 05:33AM AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey) Aug-11-23 06:07AM Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) Aug-10-23 05 ...CynergisTek, Inc. (NYSEAMERICAN:CTEK) issued its quarterly earnings results on Thursday, November, 11th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.22. The company had revenue of $3.83 million for the quarter.CRSP Stock 12 Months Forecast. Based on 16 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $85.25 with a high forecast of $220.00 and a low forecast of $42.00. The average price target represents a 21.84% change from the last price of $69.97.

Nov 22, 2023 · ACRX has an Altman Z-Score of -27.53 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for AcelRx Pharmaceuticals, Inc. (ACRX) stock, including valuation metrics, financial numbers, share information and more.

Find the latest HighPeak Energy, Inc. (HPK) stock quote, history, news and other vital information to help you with your stock trading and investing.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised ...Based on 4 Wall Street analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $21.67 with a high forecast of $47.00 and a low forecast of $8.00. The average price target represents a 452.81% change from the last price of $3.92. Highest Price Target $47.00. Average Price Target $21.67.Apr 13, 2023 · AcelRx Pharmaceuticals raised capital in December 2022, causing a roughly 50% dilution of existing shareholders on a fully diluted basis. Find out why ACRX stock is a Hold. Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Evofem Biosciences Inc have a median target of 225.00, with a high estimate of 225.00 and a low estimate of 225.00. The Adaptive Combat Rifle (ACR) is a modular assault rifle designed by Magpul Industries of Austin, Texas, and known initially as the Masada.. In late January 2008, Bushmaster Firearms International entered into a licensing agreement with Magpul whereby Bushmaster would take over production, future development, and sales of the Masada. It was then …Find real-time VRNA - Verona Pharma PLC stock quotes, company profile, news and forecasts from CNN Business.Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...2 Wall Street analysts have issued twelve-month price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price targets range from $4.25 to $5.00. On average, they expect the company's share price to reach $4.63 in the next twelve months. This suggests a possible upside of 670.8% from the stock's current price.Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. 12/31/2023. Next Earnings (Estimated) +423.4%. $-26,640,000.00.

OM Stock 12 Months Forecast. $10.20. (177.17% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Outset Medical in the last 3 months. The average price target is $10.20 with a high forecast of $19.00 and a low forecast of $3.00. The average price target represents a 177.17% change from the last price of $3.68.AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Welcome to the AcelRx third quarter 2023 financial results conference call.Nov 29, 2023 · The AcelRx Pharmaceuticals stock price gained 3.66% on the last trading day (Wednesday, 15th Nov 2023), rising from $0.464 to $0.481. During the last trading day the stock fluctuated 11.04% from a day low at $0.450 to a day high of $0.500. The price has fallen in 6 of the last 10 days and is down by -9.09% for this period. Instagram:https://instagram. what's the best platform for day tradingantares pharma incqqq returnsschwab buys td ameritrade Acelrx Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "ACRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Acelrx Pharmaceuticals Inc (ACRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 hightoweradvisorspink birkenstock barbie ACV Auctions Inc. (ACVA) share price prediction for 2023, 2024, 2025, 2026 and 2027. ACVA one year forecast. ACV Auctions stock monthly and weekly forecasts.Earnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.65) per share. AcelRx Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More. acorns alternatives Analyst Forecast. According to 2 analysts, the average rating for ACRX stock is "Strong Buy." The 12-month stock price forecast is $4.63, which is an increase of 571.11% from the latest price.The Applied Science Products, Inc. stock price gained 11.13% on the last trading day (Friday, 1st Dec 2023), rising from $4.67 to $5.19. During the last trading day the stock fluctuated 13.23% from a day low at $4.65 to a day high of $5.27. The price has risen in 6 of the last 10 days and is up by 21.26% over the past 2 weeks.AcelRx Pharmaceuticals is forecast to grow earnings and revenue by 11.4% and 63.5% per annum respectively while EPS is expected to grow by 33.4% per annum.